- Home
- CARS vs PHVS Comparison
CARS vs PHVS Comparison
Compare CARS & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARS
- PHVS
- Stock Information
- Founded
- CARS 1998
- PHVS 2015
- Country
- CARS United States
- PHVS Switzerland
- Employees
- CARS N/A
- PHVS N/A
- Industry
- CARS Motor Vehicles
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- CARS Consumer Discretionary
- PHVS Health Care
- Exchange
- CARS Nasdaq
- PHVS Nasdaq
- Market Cap
- CARS 815.4M
- PHVS 1.3B
- IPO Year
- CARS 2017
- PHVS 2021
- Fundamental
- Price
- CARS $13.33
- PHVS $24.08
- Analyst Decision
- CARS Strong Buy
- PHVS Strong Buy
- Analyst Count
- CARS 5
- PHVS 5
- Target Price
- CARS $17.30
- PHVS $35.60
- AVG Volume (30 Days)
- CARS 638.9K
- PHVS 123.2K
- Earning Date
- CARS 11-06-2025
- PHVS 11-12-2025
- Dividend Yield
- CARS N/A
- PHVS N/A
- EPS Growth
- CARS 69.36
- PHVS N/A
- EPS
- CARS 0.63
- PHVS N/A
- Revenue
- CARS $717,845,000.00
- PHVS N/A
- Revenue This Year
- CARS $2.52
- PHVS N/A
- Revenue Next Year
- CARS $2.93
- PHVS N/A
- P/E Ratio
- CARS $21.34
- PHVS N/A
- Revenue Growth
- CARS 0.68
- PHVS N/A
- 52 Week Low
- CARS $9.56
- PHVS $11.51
- 52 Week High
- CARS $20.47
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- CARS 53.22
- PHVS 58.67
- Support Level
- CARS $13.15
- PHVS $23.20
- Resistance Level
- CARS $13.84
- PHVS $24.02
- Average True Range (ATR)
- CARS 0.44
- PHVS 1.37
- MACD
- CARS -0.00
- PHVS 0.04
- Stochastic Oscillator
- CARS 52.42
- PHVS 78.51
About CARS Cars.com Inc.
Cars.com Inc is an online destination for buying and selling new and used vehicles. It is an audience-driven technology company empowering the automotive industry. The company brands include Dealer Inspire, DealerRater, FUEL, Accu-Trade, PickupTrucks.com, CreditIQ, and NewCars.com., websites directed towards different consumer segments.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.